Market closed

Entrada Therapeutics/$TRDA

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Entrada Therapeutics

Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.

Ticker

$TRDA

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Boston, United States

Employees

177

Website

www.entradatx.com

TRDA Metrics

BasicAdvanced

$473M

8.62 $1.55

-0.27

-

Price and volume

Market cap

$473M

Beta

-0.27

52-week high

$21.19

52-week low

$11.35

Average daily volume

121K

Financial strength

Current ratio

6.591

Quick ratio

6.418

Long term debt to equity

12.682

Total debt to equity

14.514

Management effectiveness

Return on assets (TTM)

6.95%

Return on equity (TTM)

16.43%

Valuation

Price to earnings (TTM)

8.621

Price to revenue (TTM)

2.201

Price to book

1.12

Price to tangible book (TTM)

1.12

Price to free cash flow (TTM)

-27.126

Growth

Revenue change (TTM)

146.92%

Earnings per share change (TTM)

-331.32%

3-year earnings per share growth (CAGR)

-63.38%

What the Analysts think about TRDA

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Entrada Therapeutics stock.

TRDA Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

TRDA Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

TRDA News

AllArticlesVideos

Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewsWire·4 weeks ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $TRDA

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Entrada Therapeutics stock?

Entrada Therapeutics (TRDA) has a market cap of $473M as of January 15, 2025.

What is the P/E ratio for Entrada Therapeutics stock?

The price to earnings (P/E) ratio for Entrada Therapeutics (TRDA) stock is 8.62 as of January 15, 2025.

Does Entrada Therapeutics stock pay dividends?

No, Entrada Therapeutics (TRDA) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Entrada Therapeutics dividend payment date?

Entrada Therapeutics (TRDA) stock does not pay dividends to its shareholders.

What is the beta indicator for Entrada Therapeutics?

Entrada Therapeutics (TRDA) has a beta rating of -0.27. This means that it has an inverse relation to market volatility.